The hearing impairment worsens over time, and most affected individuals have profound hearing loss by age 10.Individuals with Mohr Tranebjærg syndrome have normal vision during childhood, but they may develop vision problems due to breakdown of the nerves that carry information from the eyes to the brain (optic atrophy). Affected individuals can develop an increased sensitivity to light (photophobia) or other vision problems beginning in adolescence. Their sharpness of vision (visual acuity) slowly worsens, often leading to legal blindness in mid-adulthood. Genetics
This condition is caused by mutations in the TIMM8A gene. This gene is located on the long arm of X chromosome (Xq22). The protein encoded by this gene localizes to the intermembrane space in mitochondria where it functions in the import of nuclear encoded proteins into the mitochondrial inner membrane. How this produces the clinical picture is not yet clear. The pattern of inheritance is X-linked recessive. Where the female is a carrier, male offspring have a 50 percent chance of inheriting the disease and female offspring have a 50 percent chance of being a carrier. Where the male is affected, male offspring do not inherit the pathogenic mutation and females are obligate carriers.TIMM8A is also referred to as DDP. Koehler determined the function of the DDP gene and concluded that the Mohr-Tranebjaerg syndrome is a novel type of mitochondrial disease that is most likely caused by a defective mitochondrial protein-import system. Diagnosis
A combination of hearing impairment and recurrent infections due to XLA in a male patient should elicit sequencing of the TIMM8A gene.
It is used with another medication, such as chloroquine, that kills the parasites in the bloodstream.There is a need to determine whether or not tafenoquine kills the numerous, non-circulating asexual P. vivax parasites that are now known to occur in the spleen, bone marrow, and possibly elsewhere in chronic infections. Chemistry
Tafenoquine contains a stereocenter and consists of two enantiomers. This is a mixture of (R) - and the (S) - Form:

History
Tafenoquine was approved for medical use in Australia and in the United States in 2018. Tafenoquine was given an orphan drug designation and was granted breakthrough therapy status in 2013 in the United States. Society and culture
One version is made by GlaxoSmithKline. While another is made by 60 Degrees Pharmaceutical. Names
Etaquine was a generic name proposed by WRAIR, and subsequently rejected by CDER.Trade names

Kozenis (Australia)
Kodatef (Australia)
Arakoda (USA), Krintafel (USA)

References
External links
"Tafenoquine". Drug Information Portal. U.S. National Library of Medicine.